Key result
The DELETE AF trial is designed to evaluate a structured catheter ablation workflow for paroxysmal atrial fibrillation in 300 patients; efficacy and safety results are pending.
Why the study?
Residual antral potentials may contribute to AF recurrence, so the study aims to validate a workflow achieving electrical quiescence in pulmonary vein antra.
Does an improved procedural workflow for catheter ablation using high-density mapping and advanced RF technology reduce clinical atrial arrhythmias recurrence in patients with paroxysmal AF?
Population
About 300 consecutive patients with standard indications for AF ablation
Comparison
Catheter ablation of paroxysmal AF with improved procedural workflow and advanced RF technology (single arm)
Design
Prospective, single-arm, international multicenter post-market cohort study
Follow-up
12 months
Authors
Loading...
The DELETE AF study will evaluate whether a structured ablation workflow using high-density mapping and advanced RF technology improves freedom from atrial arrhythmias in patients with paroxysmal AF.
Cohort (n=300)
Yes
Does an improved procedural workflow for catheter ablation using high-density mapping and advanced RF technology reduce clinical atrial arrhythmias recurrence in patients with paroxysmal AF?
The DELETE AF study will evaluate whether a structured ablation workflow using high-density mapping and advanced RF technology improves freedom from atrial arrhythmias in patients with paroxysmal AF.
Solimene et al. (2022) conducted a cohort in Paroxysmal atrial fibrillation (n=300). Catheter ablation with high-density mapping and advanced technology was evaluated on Clinical atrial arrhythmias recurrence. The DELETE AF trial is designed to evaluate a structured catheter ablation workflow for paroxysmal atrial fibrillation in 300 patients; efficacy and safety results are pending.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: